Avutometinib and defactinib received accelerated approval for KRAS-mutated recurrent LGSOC, marking the first treatment for this specific mutation. Teliso-V was approved for advanced NSCLC with high c ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback